SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST

SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） is a phase 3, randomised interventional study registered as NCT07633873 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 500 participants, started 2026-06-02 and due to reach its primary completion in 2027-09-30. Interventions recorded: SYS6010 injection; Enlonstobart injection; Tislelizumab injection; Paclitaxel+Carboplatin or Pemetrexed + Cisplatin/Carboplatin. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Progression Free Survival (PFS) assessed by IRC. Lung eligibility wording from the registry: "Participants with pathologically confirmed locally advanced or metastatic NSCLC". No results are recorded here; the registry entry is the source.